The few small hepatic lesions detected in 40% of mice continuously treated with IFNα (Figure 3H and Figure 3—figure supplement 2C, D) did not show differences in Ki67 positivity, CD34 staining or amount of F4/80+ resident macrophages and CD3+ T cells in relation to NaCl-treated mice (Figure 3—figure supplement 2C, D), consistent with the notion that CRC tumors may deregulate the Ifnar1 receptor and, thus, become refractory to IFNα therapy (Boukhaled et al., 2021; Katlinski et al., 2017). This evidence concerns the gene IFNA1 and colorectal carcinoma.